Development of adjuvant nanocarrier systems for seasonal influenza A (H3N2) vaccine based on Astragaloside VII and gum tragacanth (APS)

Yakuboğulları, Nilgün; Genç, Rükan; Çöven, Fethiye; Nalbantsoy, Ayşe; Bedir, Erdal

doi:10.1016/j.vaccine.2019.05.038

Cited by 18 publications

(19 citation statements)

References 43 publications

(49 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Astragaloside VII, a triterpenoid saponin isolated from several Astragalus species, demonstrated a Th1/Th2-balanced antibody response along with the production of Th1 and Th17 related cytokines (i.e. IL-2, IFN-γ, IL-17A, and TGF-β) and stimulation of splenocytes to proliferate (Bedir et al, 1999;Nalbantsoy et al, 2011;Nalbantsoy et al, 2012;Yakuboğulları et al, 2019). AST-VII, the first tridesmosidic molecule isolated from natural sources, is highly polar and acid-labile, and its bioavailability from the gastrointestinal tract is questionable.…”

mentioning

confidence: 99%

Adjuvant potency of Astragaloside VII embedded cholesterol nanoparticles for H3N2 influenza vaccine

et al. 2020

Self Cite

View full text Add to dashboard Cite

Adjuvants are substances that increase the immune response to a given antigen. In the development of novel vaccine adjuvants/systems, saponins are one of the most attractive molecules due to their altered immunomodulatory activities. In this study, we tried to develop PEG (polyethylene glycol)/cholesterol-based lipid nanoparticles (LNPs) to deliver the Astragaloside VII (AST-VII) and potentiate adjuvant properties of AST-VII for the influenza vaccine. In the formation of PEG/cholesterol/AST-VII-based LNPs (PEG300: Chol-AST-VII LNPs), 3 different primary solvents (acetone, ethanol, and chloroform) were evaluated, employing their effects on hydrodynamic particle size, distribution, surface chemistry, and colloidal stability. Prepared nanoparticles were simply admixtured with inactivated influenza antigen (H3N2) and applied to PMA (phorbol 12-myristate 13-acetate)-ionomycin treated human whole blood to evaluate their cytokine release profile. PEG300: Chol-AST-VII LNPs (80.2 ± 7.7 nm) were obtained using chloroform as a desolvation agent. Co-treatment of PMA-ionomycin with AST-VII and PEG300: Chol-AST-VII LNPs significantly increased the levels of IL-2 and IFN-g, compared to PMA-ionomycin alone. In the presence of H3N2, AST-VII was able to augment IL-17A, while PEG300: Chol-AST-VII LNPs stimulated the production of IFN-g. Hemolysis was only observed in PEG300: Chol-AST-VII LNPs (250 μg/mL) treatment. AST-VII and AST-VII-integrated LNPs could be used as efficacious adjuvants for an inactivated H3N2 vaccine in vitro, and cytokine response through Th1/Th17 route was reported.

show abstract

mentioning

confidence: 99%

Adjuvant potency of Astragaloside VII embedded cholesterol nanoparticles for H3N2 influenza vaccine

et al. 2020

Self Cite

View full text Add to dashboard Cite

show abstract

“…Quercetin-7-O-glucoside was discovered in many types of Chinese herb and demonstrated a strong inhibition against influenza A and B viruses by downsizing virus-induced ROS and autophagy formation ( Gansukh et al., 2016 ). The polysaccharides extracted from the roots of astragalus mongholicus Bunge species, a famous TCM used for hundreds of years to improve QI with Chinese medicine theory, was ratified to modulate Th1/Th2 balance and secretions of IFN-γ, IL-17A, and IgG2a ( Yakuboğulları et al., 2019 ). These studies testify that different types of TCMs possess remarkable potential in immunomodulation against influenza virus.…”

Section: Basic Experimentsmentioning

confidence: 99%

Traditional Chinese Medicine in Treating Influenza: From Basic Science to Clinical Applications

Xiong

Duan

et al. 2020

Front. Pharmacol.

View full text Add to dashboard Cite

Influenza infection is a highly contagious, acute febrile respiratory disease caused by the influenza virus. Traditional Chinese Medicine (TCM) has dominated plenty of theoretical and practical approaches in the treatment of influenza. It is, therefore, important to highlight the effects of TCM in the clinical treatment of influenza and their impact on inhibiting the growth of this virus in laboratory experiments. We scrutinized existing evidence on whether TCM is effective in clinical applications. Moreover, we described the potential mechanisms of TCM against the influenza virus. Our findings provide analytical evidence that supports the effectiveness of TCM in treating influenza infections as well as their mechanisms against this virus.

show abstract

“…Yakubogullari et al introduced Astragaloside VII polysaccharide based adjuvant for influenza A vaccine. [109] Furthermore, alginate PNPs, [110] hyaluronidase combined with dextran, [111] cellulose nanomaterials, [112] inulin PNPs, [113] and cholesteryl pullulan PNPs [114] were confirmed as potential vaccine adjuvants.…”

Section: Protein Corona Stimulates or Mitigates The Immune Responsementioning

confidence: 99%

Theranostic Approach for the Protein Corona of Polysaccharide Nanoparticles

Skaličková

Horký

Mlejnková

et al. 2020

The Chemical Record

View full text Add to dashboard Cite

Polysaccharide nanoparticles are promising materials in the wide range of disciplines such as medicine, nutrition, food production, agriculture, material science and others. They excel not only in their non-toxicity and biodegradability but also in their easy preparation. As well as inorganic particles, a protein corona (PC) around polysaccharide nanoparticles is formed in biofluids. Moreover, it has been considered that the overall response of the organism to nanoparticles presence depends on the PC. This review summarises scientific publications about the structural chemistry of polysaccharide nanoparticles and their impact on theranostic applications. Three strategies of implementation of the PC in theranostics have been discussed: I) Utilisation of the PC in therapy; II) How the composition of the PC is analysed for specific disease markers; III) How the formed PC can interact with the immune system and enhances the immunomodulation or immunoelimination. Thus, the findings from this review can contribute to improve the design of drug delivery systems. However, it is still necessary to elucidate the mechanisms of nano-bio interactions and discover new connections in nanoscale research.

show abstract

Development of adjuvant nanocarrier systems for seasonal influenza A (H3N2) vaccine based on Astragaloside VII and gum tragacanth (APS)

Cited by 18 publications

References 43 publications

Adjuvant potency of Astragaloside VII embedded cholesterol nanoparticles for H3N2 influenza vaccine

Adjuvant potency of Astragaloside VII embedded cholesterol nanoparticles for H3N2 influenza vaccine

Traditional Chinese Medicine in Treating Influenza: From Basic Science to Clinical Applications

Theranostic Approach for the Protein Corona of Polysaccharide Nanoparticles

Contact Info

Product

Resources

About